Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC-311 trial. - Brose MS; Robinson BG; Sherman SI; Jarzab B; Lin CC; Vaisman F; Hoff AO; Hitre E; Bowles DW; Sen S; Oliver JW; Banerjee K; et al. (Cancer, 2022)